A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

Arch Ophthalmol. 1996 Aug;114(8):929-32. doi: 10.1001/archopht.1996.01100140137004.


Objective: To evaluate the intraocular pressure (IOP)-reducing effect and the side effects of latanoprost (PhXA41), a new phenyl-substituted prostaglandin F2 alpha-isopropyl ester analogue, in patients with elevated IOP, using timolol maleate as the reference drug.

Methods: A total of 184 patients with primary open-angle glaucoma or ocular hypertension at 35 medical centers participated in this randomized double-masked study. The patients were randomized to receive either 0.005% latanoprost once daily or 0.5% timolol maleate twice daily, for a period of 12 weeks. Intraocular pressure was measured 24 hours after the administration of timolol, at 2, 4, 8, and 12 weeks of treatment.

Results: Latanoprost reduced IOP at the end of 12 weeks by 6.2 +/- 2.7 mm Hg (mean +/- SD) (26.8%), while timolol reduced IOP by 4.4 +/- 2.3 mm Hg (19.9%). At all visits latanoprost reduced IOP significantly more than timolol did. The main ocular side effects observed in both groups were conjunctival hyperemia and smarting. The main systemic side effect was a reduced pulse rate, which occurred in patients treated with timolol.

Conclusions: The results of this study demonstrated that 0.005% latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily. Thus, latanoprost may become an important choice for the medical treatment of glaucoma.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / adverse effects
  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Conjunctiva / blood supply
  • Double-Blind Method
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Humans
  • Hyperemia / chemically induced
  • Intraocular Pressure / drug effects
  • Latanoprost
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy*
  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic / administration & dosage
  • Prostaglandins F, Synthetic / adverse effects
  • Prostaglandins F, Synthetic / therapeutic use*
  • Timolol / administration & dosage
  • Timolol / adverse effects
  • Timolol / therapeutic use*


  • Adrenergic beta-Antagonists
  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic
  • Latanoprost
  • Timolol